1. HBW Insight
  2. >>Geography
  3. >>Europe

UK Turmeric Supplement Ads Outed For Using Claims 'On Hold' At EFSA

 
• By Eileen Francis

In separate rulings, ASA upholds complains that Healthspan and Cambridge Nutraceuticals made unapproved health claims for turmeric, as the firms did not provide sufficient supporting evidence and cannot rely on similar “on hold” claims on the ingredient under review by EFSA.

Turmeric benefit claims pending at the European Food Safety Authority do not support joint health claims made by two UK marketers of turmeric dietary supplements, says the country's Advertising Standards Authority.

In separate reviews published Oct. 25, ASA reminded mail order vitamin and supplement firm Healthspan Ltd. and nutraceuticals firm Cambridge...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

AESGP Annual Meeting: European OTC Market Outlook ‘Very Positive’ Thanks To Prevention Trend

 
• By David Ridley

The European OTC market grew at double the rate of the global market in the last twelve months, according to IQVIA Consumer Health, driven by a long-term trend for prevention. Consultancy Simon Kucher identifies a desire to live a longer, healthier life as the primary concern behind this trend.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By David Ridley

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”